Since the first monoclonal antibodies (mAbs) were approved by the FDA in 1986, the field of therapeutic antibodies has advanced significantly. Early hybridoma technology produced mouse-derived antibodies, but these were limited by human antibodies developing an immune response against them. By the late 1990s, chimeric, humanized, and fully human monoclonal antibodies were developed, leading to optimization of antibody efficacy and safety.
Today, antibody-based therapeutics have expanded beyond cancer and autoimmune diseases to address infectious diseases and chronic diseases. Therapeutic antibody production is rapidly growing. The first antibody-drug conjugate (ADC) was approved in 2000, and these therapies continue to evolve. Bispecific antibodies, capable of binding two different targets, are also gaining traction, with over 85 currently in clinical trials—86% of which are being evaluated for cancer treatments. As the field continues to advance, conducting an antibody developability assessment has become essential to ensure therapeutic candidates meet critical quality, stability, and manufacturability criteria.1
The next generation of therapeutic antibodies includes bispecific antibodies, ADCs, and engineered antibody fragments. These antibody-based therapeutics offer improved targeting, higher efficacy, and fewer side effects. AI-driven drug discovery is also accelerating the development of monoclonal antibodies, with pharmaceutical companies leveraging machine learning to optimize protein structures and predict cell interactions.
The market for next-generation antibody therapeutics is expected to grow from USD 2.7 billion in 2024 to USD 6.3 billion by 2035, with a CAGR of 7.9%.2 This expansion is driven by the increasing demand for precision medicine and the ability of novel antibody formats to treat a wide range of solid tumors and hematological malignancies.
The global therapeutic antibodies market is projected to reach USD 445 billion by 2028, with a CAGR of 13.2% from 2022 to 2028. The antibody production industry alone is forecasted to reach USD 30.7 billion by 2031, with North America leading the market due to high investment in biologics and clinical research.3
Several pharmaceutical companies are expanding their product portfolio to include ADCs, bispecific antibodies, and nanobody-based therapies. With over 90 therapeutic agents currently in Phase I–III clinical trials, the antibody-based therapeutics industry is set for sustained growth.
Related: HTP Recombinant Antibody Production
Despite advancements, therapeutic antibodies face challenges:
Antibody Developability: Not all monoclonal antibodies can be manufactured at scale. Predictive analytics are now used to assess protein stability, solubility, and immunogenicity.
Complex Design: Bispecific antibodies and antibody-drug conjugates require precise engineering to ensure stability and efficacy. ADCs must maintain optimal conjugate ratios for effective drug delivery.
Cost: Antibody production remains expensive. Pharmaceutical companies are investing in AI-driven optimization and single-use bioprocessing to reduce costs and improve efficiency.
The future of monoclonal antibodies will be defined by:
AI-Driven Discovery: Computational tools will refine antibody sequences, enhancing specificity and manufacturability.
Personalized Medicine: Biomarker-based therapeutic antibodies will improve treatment precision for chronic diseases and infectious diseases.
Combination Therapies: ADCs, bispecific antibodies, and immune checkpoint inhibitors will improve patient outcomes in oncology and autoimmune diseases.
Manufacturing Innovation: Advances in antibody-drug conjugate chemistry and bispecific antibody design will expand their clinical applications.
With over 450 therapeutic antibodies in development, the industry is poised for continuous innovation. The integration of AI, precision medicine, and novel antibody-based therapeutics will shape the next era of antibody therapy, ensuring better treatments for a wide range of diseases.
At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs, including VHH Antibody Discovery, Single B Cell Screening, Hybridoma Sequencing, and High-throughput Fully Human Antibody Discovery. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Lu, R.-M., Hwang, Y.-C., Liu, I-Ju., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020). Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 27(1). https://doi.org/10.1186/s12929-019-0592-z
Roots Analysis. (2022, June 20). Next-Generation Antibody Therapeutics Market Report 2035. Rootsanalysis.com; Roots Analysis. https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html#overview
Lyu, X., Zhao, Q., Hui, J., Wang, T., Lin, M., Wang, K., Zhang, J., Shentu, J., Dalby, P. A., Zhang, H., & Liu, B. (2022). The global landscape of approved antibody therapies. Antibody Therapeutics, 5(4), 233-257. https://doi.org/10.1093/abt/tbac021
Artificial intelligence is quickly becoming part of monoclonal antibody discover……
Explore fluorescent VHH probes for high-resolution detection, cell imaging, and ……
Discover how VHH antibodies enhance ELISA platforms with high sensitivity, stabi……
Explore how VHH in lateral flow assay development improves rapid diagnostics thr……
You can also contact us on the Scientist and Science Exchange marketplaces.